Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction
- Disease/Condition
- Myocardial Infarction
- Drug/Device/Intervention
- Alcohol consumption
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Baris Gencer
- Funder
- University Hospital, Geneva
- Location
- Bern,Geneve, Switzerland
- Phase
- N/A
- Start date
- Jun 01, 2023
- End date
- Apr 30, 2026
- Enrollment
- 220 participants
Cardiac function
A total of 220 patients (110 per arm) who report moderate alcohol consumption between 4 and
 28 standard units (1 standard unit = ~10 grams) per week in the 12 months prior to hospital
 admission will be planned for randomization, using a 1:1 ratio to pursue moderate alcohol
 consumption (1 standard unit per day for women and 2 standard units per day for men for 12
 months) or abstinence (except for one drink on predefined/agreed special occasions) for a
 total duration of 12 months. An echocardiography will be performed at baseline and 12 months
 to assess changes in systolic cardiac function (LVEF) for the primary endpoint. A core
 laboratory team blinded to assignment will perform data interpretation.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05920629
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05920629 through Pure Global AI's free database. This phase not specified trial is sponsored by Baris Gencer and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 220 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.